Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
AChR-Ab Seropositive Generalized Myasthenia Gravis: early-phase trial registry
2 of 2 indexed AChR-Ab Seropositive Generalized Myasthenia Gravis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,203 of 28,963 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,203 of 28,963 conditions by registered trial count
AChR-Ab Seropositive Generalized Myasthenia Gravis: 2 US clinical trials tracked, 2 recruiting.
AChR-Ab Seropositive Generalized Myasthenia Gravis is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 2 of these trials.
Open enrollment, early-phase tilt
AChR-Ab Seropositive Generalized Myasthenia Gravis has 2 registered US clinical trials, 2 of them open to new participants right now, about 100% of the total.
- 2
- recruiting participants now
- 100%
- of trials open to enrollment
- 0
- in Phase 3-4 (later-stage)
- 2
- top sponsor: argenx
Corpus placement: #7,203 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for AChR-Ab Seropositive Generalized Myasthenia Gravis on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
AChR-Ab Seropositive Generalized Myasthenia Gravis is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
NCT07294170
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
NCT07284420
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for AChR-Ab Seropositive Generalized Myasthenia Gravis right now
2 recruiting of 2 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top sponsor: argenx (2 trials), 0 others listed. 2 shown below, recruiting first. #7,203 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for AChR-Ab Seropositive Generalized Myasthenia Gravis?
PlainTrial tracks 2 US clinical trials for AChR-Ab Seropositive Generalized Myasthenia Gravis, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for AChR-Ab Seropositive Generalized Myasthenia Gravis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.